Hikma launches Fidaxomicin Tablets as Hikma stock awaits update

Published on 10/18/2026 at 13:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The US launch adds four tablet strengths to Hikma's portfolio. Hikma stock has a November 5 trading update and a 20 October R&D seminar.

Product launches and investor dates

Fidaxomicin Tablets launched in the United States on October 15, 2026, in a 200mg strength.
Branded revenue grew 15 percent in the first half of 2026, according to Hikma.
Hikma's next trading update is scheduled for November 5, 2026.

Fotorealistische sterile Pharma-Produktionslinie mit Injektionsfläschchen und Edelstahlanlagen — Hikma Pharmaceuticals PLC GB00B128J450 zeigt moderne Injektions-Produktionslinie in sterilem Pharmawerk mit Edelstahlanlagen, Illustration mit AI erstellt.

Hikma Pharmaceuticals (ISIN GB00B0LCW083) launched Fidaxomicin Tablets in the United States on October 15, 2026, adding a 200mg product to its portfolio, according to Hikma. The product is indicated for adults with Clostridioides difficile-associated diarrhea.

Two US launches in October

The latest launch followed Hikma's October 14, 2026 launch of Deflazacort Tablets in four strengths for patients aged 2 years and older. Hikma said IQVIA put US sales of the product at USD 25 million for the 12 months ending June 2026. The company said the product is manufactured at its Columbus, Ohio facility.

What does the pipeline add?

Hikma's first-half 2026 performance gives the product activity a broader operating context. On its investor-relations page, Hikma said Branded revenue grew 15 percent in the first half of 2026 and that it reiterated its full-year 2026 guidance. The company also said Hikma Rx delivered profit growth and margin expansion during the period.

Three dated steps in the story

On September 24, 2026, Hikma appointed Rebecca Hall as chief financial officer, with her arrival planned for the first quarter of 2027. On October 14, 2026, it launched Deflazacort Tablets in four strengths, and on October 15, 2026, it launched Fidaxomicin Tablets in a 200mg strength. The two product releases were reported by Hikma and Hikma.

Dates that matter next

Hikma has scheduled an R&D seminar for October 20, 2026, covering respiratory, nasal, semi-solid and liquid products. The company has also scheduled its next trading update for November 5, 2026, according to its R&D investor announcement. The seminar is educational, while the November date is the next planned trading communication.

LSE quote and company profile

Hikma's last LSE quote was GBp 1,662.00 on October 16, 2026 at 4:35 p.m. London time. The 52-week range was GBp 1,187.00 to GBp 1,865.00. Hikma's portfolio now includes two newly launched US products alongside its established Injectables, Branded and Hikma Rx businesses.

The further course of trading is shown by the continuously updated real-time quote of Hikma stock.